Recently, increasing evidence showed that FGF2 was important in the pathogenesis of haematological malignant tumours [34–38], such as chronic myeloid leukaemia (CML), chronic lymphoid leukaemia (CLL) and Hodgkin’s lymphoma. Here, FGF2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.